title: The involvement of dopamine and nitric oxide in the endocrine and behavioural action of endomorphin-1.
abstract: Previous publications have demonstrated a prominent central and corticotropin releasing hormone-mediated action of the endomorphins (EMs) on both open-field behaviour and the hypothalamo-pituitary-adrenal (HPA) axis. In the present experiments, the direct action of endomorphin-1 (EM1) on pituitary adrenocorticotropic hormone (ACTH) release, adrenal corticosterone secretion and the roles of nitric oxide (NO) and dopamine (DA) in the HPA and behavioural responses elicited by EM1 were investigated in mice. In vitro perifusion studies indicated that the action of EM1 on the HPA system appears to be confined to the hypothalamus, as EM1 did not influence the corticosterone secretion from adrenal slices and moderately attenuated the ACTH release from anterior pituitary slices. In in vivo experiments, NG-nitro-L-arginine (L-NNArg) pretreatment brought about a profound inhibition of both the endocrine and the behavioural responses. On the other hand, haloperidol completely abolished the increases in square crossing and rearing, without affecting corticosterone release. The direct action of EM1 on striatal DA release was therefore also investigated in an in vitro superfusion system. Although EM1 did not influence the basal release of tritiated DA, it significantly enhanced the transmitter release evoked by electric impulses and pretreatment with L-NNArg resulted in a considerable inhibition of the release elicited by EM1. In conclusion, our endocrine studies suggest an important role of NO in the mediation of the EM1-evoked corticosterone secretion. They also indicate that EM1 activates the HPA axis at a hypothalamic level and dopamine is not involved in this process. In contrast, the behavioural experiments reflect that the locomotor activation induced by EM1 is mediated by NO and dopamine, and the superfusion studies demonstrate that NO transmits the dopamine release enhancing effect of EM1.
authors.affiliation: University of Szeged, Department of Pathophysiology, Albert Szent-Gyorgyi Medical and Pharmaceutical Centre, Neurohumoral Research Group of Hungarian Academy of Sciences, PO Box 427, 6701 Szeged, Hungary.
authors.forename: E
authors.initials: E
authors.lastname: Bujdosó
authors.forename: M
authors.initials: M
authors.lastname: Jászberényi
authors.forename: J
authors.initials: J
authors.lastname: Gardi
authors.forename: I
authors.initials: I
authors.lastname: Földesi
authors.forename: G
authors.initials: G
authors.lastname: Telegdy
mesh_terms: D000324:Adrenocorticotropic Hormone / Q000097:blood; D000818:Animals; D004298:Dopamine / Q000378:metabolism / Q000502:physiology*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects* / Q000502:physiology; D008297:Male; D051379:Mice; D009043:Motor Activity / Q000187:drug effects* / Q000502:physiology; D009569:Nitric Oxide / Q000037:antagonists & inhibitors / Q000502:physiology*; D009842:Oligopeptides / Q000494:pharmacology*; D010913:Pituitary-Adrenal System / Q000187:drug effects* / Q000502:physiology
chemical_list: D004791:Enzyme Inhibitors; D009842:Oligopeptides; C105293:endomorphin 1; D009569:Nitric Oxide; D000324:Adrenocorticotropic Hormone; D004298:Dopamine